Edition:
United States

Quest Diagnostics Inc (DGX)

DGX on New York Consolidated

98.70USD
24 Mar 2017
Change (% chg)

$0.43 (+0.44%)
Prev Close
$98.27
Open
$98.39
Day's High
$99.21
Day's Low
$98.27
Volume
884,005
Avg. Vol
968,416
52-wk High
$100.00
52-wk Low
$68.91

DGX

Chart for DGX

About

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower... (more)

Overall

Beta: 0.69
Market Cap(Mil.): $13,570.78
Shares Outstanding(Mil.): 137.50
Dividend: 0.45
Yield (%): 1.82

Financials

  DGX Industry Sector
P/E (TTM): 21.73 32.52 29.94
EPS (TTM): 4.54 -- --
ROI: 7.79 5.61 13.01
ROE: 13.77 8.84 14.16

BRIEF-Vermillion say co, unit entered amendment No. 2 to testing, services agreement with Quest Diagnostics effective March 11, 2017

* Vermillion - co, unit entered amendment no. 2 to testing and services agreement with quest diagnostics incorporated effective March 11, 2017

Mar 13 2017

BRIEF-QUEST DIAGNOSTICS SAYS WILL ACQUIRE OUTREACH LABORATORY SERVICES OPERATIONS OF PEACEHEALTH LABORATORIES

* QUEST DIAGNOSTICS AND PEACEHEALTH FORMED TWO-PART ARRANGEMENT TO ENHANCE DELIVERY OF LABORATORY SERVICES TO COMMUNITIES IN OREGON, WASHINGTON, ALASKA

Feb 15 2017

BRIEF-Quest Diagnostics Partners with Montefiore Health System to deliver high-value, innovative laboratory services

* Quest Diagnostics Partners with Montefiore Health System to deliver high-value, innovative laboratory services

Jan 26 2017

BRIEF-Quest Diagnostics launches hepatitis b virus quantitative test

* Launches hepatitis b virus quantitative test to help assess response to antiviral therapy Source text for Eikon: Further company coverage:

Jan 18 2017

BRIEF-Quest diagnostics raises revenue growth outlook and increases dividend

* Quest Diagnostics has raised its common stock dividend by 12.5 pct to an annual rate of $1.80 per share

Nov 11 2016

BRIEF-Genomic Vision presents initial results of the pilot study undertaken with Quest Diagnostics in SMA

* Presents The Initial Results Of The Pilot Study Undertaken With Quest Diagnostics In Spinal Muscular Atrophy (SMA) At The Ashg 2016 Annual Meeting In Vancouver Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 20 2016

More From Around the Web

Competitors

Earnings vs. Estimates